医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Pharm-Olam Continues Global Expansion; Adds Full-Service Coverage in Asia-Pacific Region

2016年01月13日 AM01:47
このエントリーをはてなブックマークに追加


 

HOUSTON

Pharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization to the biopharmaceutical and medical device industries, is proud to announce its expansion of Phase I-IV clinical trial services into the Asia-Pacific region.

This expansion includes the opening of legal entities in Vietnam, Philippines, South Korea, Malaysia, Thailand and Taiwan.

“In response to requests coming in from our clients, we have begun expanding our services into the Asia-Pacific region,” said Sanjiv Suri, Pharm-Olam’s Chief Executive Officer (USA). He continued, “We anticipate significant study growth in the region over the next few years, and we are now poised to guide our clients in the development process in these promising yet often overlooked markets.”

Suri added, “The successes we’ve shared have been a result of offering our clients solutions for their unique needs. Our Asia-Pacific expansion efforts will allow us to offer comprehensive and flexible solutions in a timely and efficient manner. We look forward to continuing to support our clients globally.”

For more information about Pharm-Olam and its global Phase I-IV clinical research solutions, contact info@pharm-olam.com.

About Pharm-Olam International Group

Pharm-Olam International is a multi-national Contract Research Organization (CRO) offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines. For further information about Pharm-Olam, please visit www.pharm-olam.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160112006251/en/

CONTACT

Pharm-Olam International
Mark Eberhardt, +1-713-599-7350

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 中国のヘルスケア市場は今後15年間で投資と機会が急拡大の見込み
  • Dr. Reddy’s and Integra LifeSciences Enter into an Agreement to Market and Distribute DuraGen Plus® and Suturable DuraGen® Dural Regeneration in India
  • Latest clinical research confirms that IQOS reduces smoker exposure to select harmful chemicals as compared to cigarette smoke
  • 中国医疗市场将在未来15年内迎来投资热潮和诸多机遇
  • NZMP GOLD Whole Milk Powder for UHT Launches